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Reproductive functionsmay be altered by the exposure to amultitude of endogenous and exogenous agents, drug or environmental
pollutants, which are known to affect gene transcription through the peroxisome proliferator-activated receptors (PPARs)
activation. PPARs act as ligand activated transcription factors and regulate metabolic processes such as lipid and glucose
metabolism, energy homeostasis, inflammation, and cell proliferation and differentiation. All PPARs isotypes are expressed along
the hypothalamic-pituitary-gonadal axis and are strictly involved in reproductive functions. Since female fertility and energy
metabolism are tightly interconnected, the research on female infertility points towards the exploration of potential PPARs
activating/antagonizing compounds,mainly belonging to the class of thiazolidinediones (TZDs) and fibrates, as useful agents for the
maintenance of metabolic homeostasis in women with ovarian dysfunctions. In the present review, we discuss the recent evidence
about PPARs expression in the hypothalamic-pituitary-gonadal axis and their involvement in female reproduction. Finally, the
therapeutic potential of their manipulation through several drugs is also discussed.
1. PPARs
Peroxisome proliferator-activated receptors (PPARs) are lig-
and activated transcription factors belonging to the nuclear
receptor family; three isotypes have been identified so far:
PPAR𝛼, PPAR𝛽/𝛿, and PPAR𝛾, from frogs to humans [1].
A multitude of agents can bind the PPARs, influencing
their activity. Endogenous compounds include arachidonic
acid and its eicosanoid metabolites [2–4], while synthetic
ligands are principally represented by fibrates (hypolipidemic
drugs) [5], thiazolidinediones (TZDs) (antidiabetic drugs)
[6], and nonsteroidal anti-inflammatory drugs [7]. PPARs
can be also activated by environmental pollutants such as
certain phthalate esters (plasticizers), herbicides, and organic
solvents [8]. The binding specificity of these compounds
towards PPAR subtypes is not strict; that is, several
prostaglandins activate all three PPAR subtypes, while most
fibrates and TZDs selectively bind to PPAR𝛼 and PPAR𝛾,
respectively [9]. After ligand binding, PPARs undergo a
conformational change resulting in the dissociation of core-
pressors [10, 11] and recruitment of coactivators [11]. PPARs
heterodimerize with the 9-cis-retinoic acid X receptor (RXR,
NR2B) to form PPAR/RXR complex that binds to a specific
DNA sequence called PPAR-responsive element (PPRE),
usually 5󸀠-AACT AGGNCA A AGGTCA-3󸀠 [10]. The PPRE
is usually located in the promoter region of key target
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genes mainly involved in lipid and cholesterol metabolism
[10, 12, 13], cell differentiation [14, 15], organogenesis [16],
antiangiogenic activity [17], and insulin sensitization [18].
The PPAR family is known to adapt cell metabolism to
lipid/glucose availability by controlling energy homeostasis
genes. All three PPAR isotypes regulate endocrine path-
ways.
PPARs are expressed in the female hypothalamic-pitu-
itary-gonadal axis and they act on critical processes for
ovarian function. For instance, PPARs/RXRs may inhibit
transactivation of the estrogen receptor through competition
for ERE binding [19]. It is known in porcine ovarian follicles
that PPAR𝛾 can downregulate aromatase expression through
the suppression of NF-𝜅B pathway [20] and that its synthetic
activator rosiglitazone is able to stimulate PPAR𝛾 expression
affecting the expression of important enzymes involved in
steroidogenesis [21]. Regarding PPAR𝛼, in vivo experiments
in mouse ovaries showed that fenofibrate inhibits gene
expression of enzymes involved in ovarian estrogen synthe-
sis and that a functional PPAR𝛼 is indispensable for this
inhibitory action [22].
All the three PPAR isotypes regulate gametogenesis, ovu-
lation, corpus luteum regression, and the implantation pro-
cess [1, 23]. Regarding male gametogenesis mRNAs encoding
PPAR𝛼, PPAR𝛽/𝛿, andPPAR𝛾 are developmentally expressed
in both differentiating germ and Sertoli cells; particularly,
PPAR𝛾 regulates the pattern of expression of key lipid
metabolic genes in Sertoli cells [24].
In situ hybridization studies on rat ovary collected during
follicular development and periovulatory period, by Komar
and colleagues [25], demonstrated that PPAR𝛾 mRNA is
localized primarily into granulosa cells and that its expression
does not change during follicular development; in contrast
the treatment of animals with human CG (hCG) leads after
24 h to a not uniform decrease of PPAR𝛾. Particularly, at
24 h after hCG the levels of PPAR𝛾mRNA appeared reduced
of 64%, but some follicles maintained high expression.
PPAR𝛼 and PPAR𝛽/𝛿mRNA levels, mainly present in theca
and stroma cells, do not change even upon treatment. In
vitro study confirmed that PPAR𝛾 is involved in follicular
development, since, in granulosa cells from PMSG-primed
rats cultured for 48 h with PPAR𝛾 ligands, an increase of
progesterone and E2 secretion is observed [25].
The effect of PPAR𝛾 on progesterone synthesis depends
on cell type, stage of cell differentiation, stage of the ovarian
cycle, and/or animal species [26].
For instance, the role of PPAR𝛾 was investigated in
corpora lutea of pseudopregnant rabbits at early, middle, and
late stage. BothmRNA and protein levels of PPAR𝛾 decreased
from the early to the late stage. In vitro studies on corpora
lutea treated with PPAR𝛾 agonist show that the agonist is able
to increase progesterone secretion and 3-beta-hydroxysteroid
dehydrogenase (3-beta-HSD) activity at early and mid luteal
stages, while decreasing at the same stages prostaglandin-
endoperoxide synthase 2 (PTGS2) activity and prostaglandin
F2a. Treatments with a specific antagonist of PPAR𝛾 have
opposite effects [27]. Quantitative analysis of PPARs mRNA
in porcine endometrium through the estrous cycle and early
pregnancy showed the presence of all three PPARs in this
tissue. Particularly, this analysis showed a marked increase of
PPAR𝛾mRNA level on days 13–15 of the estrous cycle and the
decrease of PPAR𝛽/𝛿 on days 11-12 of pregnancy suggesting
that PPARs are engaged, respectively, in luteolysis (corpus
luteum regression) and maternal recognition of pregnancy in
the pig [28]. In addition, PPAR ligands affect progesterone
(P4) and 17b-estradiol (E2) secretion by porcine corpus
luteum during pregnancy [29].
PPAR𝛽/𝛿 seems to play an important role in embryo
implantation; in fact, several lines of evidence suggest that the
effects of PGI2, the primary PG essential for implantation and
decidualization, are mediated by PPAR𝛽/𝛿 [30]. Moreover,
using molecular, pharmacologic, and genetic approaches,
Kang and colleagues, 2001, showed that PGI2-induced
PPAR𝛽/𝛿 activation accelerates blastocyst hatching in mice
[31].
Furthermore, PPARs expression can be modulated by
gonadotropin activity; that is, PPAR𝛾mRNA and protein lev-
els are tightly regulated in the ovary by luteinizing hormone
(LH) in rat [32] and in rhesus monkey granulosa cells [33].
Particularly, the data obtained in primates showed that one
of the initial actions of LH/CG on preovulatory follicle is to
rapidly reduce PPAR𝛾 expression and its target gene NR1H3,
enzyme that promotes the expression of periovulatory genes,
such as SCARB1 and STAR [33].
Moreover, gene array study conducted on human cumu-
lus cells has revealed that PPAR𝛼 is among the genes differ-
entially expressed when LH is supplemented to FSH during
in vitro fertilization [34].
Recently we found differential effects of controlled ovar-
ian stimulation COS protocols on PPARs and their steroido-
genic targets in relation to LH and gonadotropin source.
Particularly, the analyses of gene and protein expression of
PPAR𝛼, PPAR𝛽/𝛿, and PPAR𝛾 have revealed that r-hLH
associated with r-hFSH exposure influence all the three
PPARs by modulating the relative abundance of the different
isotypes. In particular, a significant reduction of PPAR𝛼
protein was observed, although mRNA levels did not sig-
nificantly change. PPAR𝛽/𝛿 and PPAR𝛾 were significantly
upregulated upon r-hFSH/r-hLH treatment [35].
Finally, PPARs/RXRs, as exposed above, may inhibit
transactivation of the estrogen receptor through competition
for ERE binding mediating also the effects of the endocrine
disruptors, many of which are PPAR ligands. These events
may lead to infertility as demonstrated in many aquatic
species and also in rodents. In fact, in several species, PPARs
are expressed in somatic cells and germ cells of the ovary
as well as the testis. Invalidation of these receptors in
mice or stimulation of these receptors in vivo or in vitro
showed that each receptor has physiological roles in the
gamete maturation or the embryo development. In addition,
synthetic PPAR𝛾 ligands are recently used to induce ovulation
in women with polycystic ovary disease. These results reveal
the positive actions of PPAR in reproduction. On the other
hand, xenobiotics molecules (in herbicides, plasticizers, or
components of personal care products), capable of activating
PPAR, may disrupt normal PPAR functions in the ovary or
the testis and have consequences on the quality of the gametes
and the embryos [1].
PPAR Research 3
2. Female Reproductive System
Thefemale reproductive system requires precise coordination
among the hypothalamic gonadotropin-releasing hormone
(GnRH), the pituitary gonadotropins, the ovaries, and the
uterus. The pituitary gland responds to GnRH pulses
by releasing two gonadotropins: follicle stimulating
hormone (FSH) and luteinizing hormone (LH). The FSH
activity during the early-midfollicular phase is critical for
recruitment and maturation of ovarian follicles, expression
of LH receptors, and differentiation of an endocrinologically
active theca layer capable of synthesizing androgens in
response to LH [36]. Androgens are then aromatized to
estradiol by the granulosa cells. The increase of estradiol
and ovarian production of the inhibins, peptides that inhibit
pituitary gland synthesis and secretion of FSH, reduces
FSH levels, enhances LH responsiveness, and induces
the LH surge [37]. LH levels remain increased for 36–48
hours and ovulation occurs 16 to 20 hours after the peak
of LH surge. Resumption of meiosis and progression to
the second meiotic metaphase and polar body extrusion
take place just prior to ovulation. After the release of
the oocyte-cumulus complex, estradiol levels decline and
luteinization of the follicle results in increased production
of progesterone [38]. The rise in progesterone levels induces
a significant decrease in GnRH/LH pulse frequency and
prepares the genital tract for a possible embryo implantation
by increasing secretory activity of the endometrial glands
and by changing composition of the cervical mucus that
becomes thick and viscous [39]. Therefore, the ovarian
cycle requires a fine coordination of the hypothalamic-
pituitary-gonadal axis and follicular growth to drive
steroidogenesis that culminates in the ovulation of a fully
competent oocyte. Altered secretion of gonadotropins
and poor ovarian steroidal response are associated with
reproductive dysfunctions [40, 41] characterizing a large
percentage of womenwho undergo in vitro fertilization (IVF)
treatments. In IVF, the gonadotropin therapy plays a pivotal
role in ovarian stimulation and influences egg retrieval,
fertilization, embryo culture, and intrauterine transfer
[42].
3. The Role of PPARs in
Female Reproductive Function
A multitude of studies have revealed that PPARs are func-
tionally expressed in the whole female reproductive system
indicating that PPARs may play an important role in repro-
duction mostly due to their implication in energy homeosta-
sis (Figure 1). Moreover, a role for PPARs has been evoked in
ovarian dysfunctions related to obesity [43, 44], dyslipidemia
[45, 46], hyperandrogenemia [47–50], and insulin resistance
[51–54].
3.1. Hypothalamic-Pituitary Axis. All PPAR isotypes are
expressed in the mouse pituitary gland [55]; recent evidence
in rats has demonstrated that fasting increases mRNA levels
of PPAR𝛼 targets implicated in 𝛽-oxidation of fatty acids,
such as acyl-CoA oxidase, carnitine palmitoyltransferase-1,
medium chain acyl-CoA dehydrogenase, and ketogenesis,
that is, mitochondrial 3-hydroxy-3-methylglutaryl-CoA syn-
thase in the pituitary gland. Furthermore, studies on PPARa
null mice have revealed that PPAR𝛼 increases pituitary
production of prolactin and LH-beta genes upon fasting
[56].
PPAR𝛾 is known to be highly expressed in normal human
pituitary gland [57] and in the rat hypothalamus [58, 59].
It was reported that PPAR𝛾 activation by TZDs prevented
the development of pituitary adenomas in mice and humans
due to its antiproliferative effects, so TZDs are proposed
as novel oral therapy for pituitary tumors [60]. PPAR𝛾
expression and function in the hypothalamopituitary-ovary
axis in the sheep were studied by Froment and colleagues,
2003. They found that PPAR𝛾 is expressed in the pituitary
gland but not in the hypothalamus and through transient
transfection experiments on pituitary cells with a vector
containing PPREs driving the firefly luciferase gene (PPRE-
Luc); they found a small but significant effect of rosigli-
tazone on endogenous pituitary PPAR𝛾, indicating that it
is functional and could play a physiological role in this
tissue [61]. Since the precise role of PPAR𝛾 in regulating
the hypothalamic-pituitary-gonadal axis remains unclear,
recently Sharma and colleagues, 2011, had tried to dissect
the role of this transcriptional factor in the pituitary gland
[62]. They showed that rosiglitazone downregulates GnRH-
mediated phosphorylation of the JNKs and p38MAPKs and
Lhb and Fshb gene expression in L𝛽T2 cells. Thus, the
PPAR𝛾 activation could act by reducing the basal activity
of the gonadotropin gene promoters. Since these kinases
are activated by many cytokines and inflammatory signals,
the authors hypothesize that the TZD effect is consistent
with its known anti-inflammatory actions. The same authors
moreover showed that pituitary gland cre PPARg-knockout
(PKO) mice have elevated plasma LH and reduced litter
size compared to the control cre-negative littermates. Female
PKO mice present also fertility defects like the transgenic
mice with 10- to 12-fold overexpression of a stabilized
form of LH. These observations support a possible role for
PPAR𝛾 in modulating pituitary gland function in vitro and in
vivo.
As regards PPAR𝛽/𝛿 very little is known about its role in
this tissue.
3.2. Ovary. The basic unit of the ovary is the follicle, a
functional syncytium formed by the oocyte and surrounding
follicle cells. During reproductive life, a number of oocytes
from the pool of quiescent follicles progress to mature and
ovulate. Once recruited in the growing phase, primordial fol-
licles develop into primary, secondary, and eventually antral
follicle reaching the preovulatory stage under gonadotropin
stimulation. The antral follicle is characterized by the pres-
ence of an antrumfilledwith follicular fluid bathing an oocyte
surrounded by cumulus cells.The inner lining of the follicle is
formed by granulosa cells, which are principally responsible
for the androgens-estrogens conversion.The outer boundary
is defined by theca cells, which form a vascularized cell layer
that provides androgens to granulosa cells. Upon the LH
surge, the dominant follicle ovulates the mature oocyte that
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PPAR𝛽/𝛿: little is known about its role
in this tissue [55].
PPAR𝛾 modulates pituitary gland function
in vitro and in vivo [60, 61, 62].
PPAR𝛼 and PPAR𝛽/𝛿 are expressed primarily
in the theca and stroma tissues [65].
PPAR𝛾 is highly expressed in granulosa cells
and it is identified at all stages of follicular development;
its expression increases with follicle development and
decreases after the LH surge [25, 26].
PPAR𝛽/𝛿: little is known about its role in this tissue.
PPAR𝛼 and PPAR𝛾 are involved in follicular rupture during
ovulation and corpus luteum formation [72, 73].
In addition, PPAR𝛾 seems to influence the granulosa 
cells/oocyte cross talk supporting their mutual maturation;
its ligand improves oocyte developmental competence [26, 70].
Metabolism of steroid hormones is affected by PPARs
[32, 33, 34, 35].
PPARs are differently expressed in these
tissues in the different species.
PPARs play important roles as key-factors
controlling the process of implantation,
trophoblast differentiation, and placenta
vascularization [31, 78, 96].
PPAR𝛼 and PPAR𝛾 are downregulated
during pregnancy and lactation [97].
PPAR𝛽/𝛿 mRNA remains relatively
unchanged during these processes [97].
MSE cells-specific PPAR𝛾 loss creates
a protumorigenic environment [102].
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Figure 1: PPARs expression and role in the whole female reproductive system.
is ready for fertilization, whereas the remaining theca and
granulosa cells become the corpus luteum that contributes
to the production of circulating progesterone [63, 64]. All
PPAR isotypes have been observed in the ovarian tissue.
PPAR𝛼 and PPAR𝛽/𝛿 are expressed primarily in the theca
and stroma tissues [65]. PPAR𝛾 expression has been reported
in the ovaries of mouse, rat, pig, sheep, cow, and humans,
with higher levels in granulosa cells and lower levels in
theca cells and corpus luteum of rodents and ruminants
[66]. In particular, PPAR𝛾 has been identified in follicles
at all stages of development and it has been shown that
levels increase during follicle growth and decrease after the
LH surge [25, 26]. In the rat, PPAR𝛾 levels are lower in
newly forming luteal tissue when compared with that in
luteal tissue from previous ovulation [67]. PPAR𝛾 has also
been identified in oocytes from cattle [68] and zebrafish [69],
suggesting an evolutionary conserved role for this isotype in
female germ cells. Since PPAR𝛾 expression is predominant
in granulosa cells, it can be hypothesized that its activity
influences the granulosa cell/oocyte cross talk, supporting
their mutual maturation [26]. In this respect, some studies
have investigated the possible effects of PPAR𝛾 activation
on oocyte maturation. In vivo administration of PPAR𝛾
agonist rosiglitazone in diet-induced obese mice significantly
improves oocyte competence supporting the conclusion that
PPAR𝛾 positively affects ovarian functions [70]. However
direct exposure to rosiglitazone does not produce the same
effects in cumulus-oocyte complexes from normal mice.
In this experimental system, although oocyte mitochon-
drial activity increases, fatty acid metabolism decreases and
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subsequent impairment of embryo development was ob-
served [71]. The discrepancy between these studies may be
explained by considering that beneficial effects of PPAR𝛾
activation in obese mice may result from systemic effects
such as reduced circulating insulin and lipid. In addition
it can be hypothesized that only oocytes with large lipid
availability as those from obese mice may benefit from
increased PPAR𝛾 activity. These observations may be use-
ful for investigating potential ability of PPAR𝛾 agonists to
improve oocyte competence following in vitromaturation in
obese females. Finally, several proteases involved in follicular
rupture during ovulation and corpus luteum formation,
such as matrixmetalloprotease-9, plasminogen activator, and
plasminogen activator inhibitor, are regulated by PPAR𝛼 and
PPAR𝛾 [72, 73]. In contrast, very little is known about the role
of PPAR𝛽/𝛿 in this tissue.
Regarding ovarian function, it is well documented that
the synthesis and metabolism of steroid hormones are
affected by all PPARs. PPAR𝛼 positively regulates 17𝛽-
hydroxysteroid dehydrogenase IV (17 𝛽-HSD IV), the
enzyme that catalyzes the conversion of 17𝛽-estradiol to
estrone, its inactive form [74]. Although PPAR𝛼 expression is
very low in granulosa cells [25, 67], it was demonstrated that
its activation is responsible for decreasing the expression and
activity of aromatase [22]. In addition, dietary supplemen-
tation of dehydroepiandrosterone (DHEA), a PPAR𝛼 ligand
and precursor of androstenedione, has recently emerged as
a beneficial intervention for increasing oocyte quality in
poor responders and aged women [75, 76]. According to a
model proposed by Ford [75], DHEA action may involve
the activation of PPAR𝛼 target genes known to be critical
for mitochondria functions. Thus, upregulation of PPAR𝛼 in
the follicle microenvironment may support oxidative energy
metabolism known to be jeopardized during physiological
or pathological ovarian aging [77]. Moreover, the beneficial
action by DHEA throughout PPAR𝛼 activation could be
also ascribed to diminished levels of ceramide, a molecule
involved in increased levels of apoptosis in aged follicles [75].
Furthermore, a gene array study conducted on human cumu-
lus cells has revealed that PPAR𝛼 and RXR𝛽 were among
the genes differentially expressed when LH is supplemented
to FSH during IVF [34], thus highlighting their sensitivity
to gonadotropins and suggesting their important role in
follicle development as well as in steroidogenesis. In a recent
study by our research group, we investigated the impact
of different ovarian stimulation regimens based on r-hFSH
alone, r-hFSH/r-hLH, or highly purified human menopausal
gonadotropin (hMG-HP) on gene and protein expression
of PPAR isotypes and their targets relevant to steroid
metabolism, such as 3-hydroxy-3-methylglutaryl coenzyme
A reductase (HMG-CoA red), cytochrome P-450 (CYP19A1),
17𝛽-hydroxysteroid dehydrogenase type IV (17𝛽HSD IV),
and 3𝛽-hydroxysteroid dehydrogenase type 2 (3𝛽HSD II) in
granulosa cells [35]. We also demonstrated that PPARs and
their steroidogenic targets are influenced by the presence and
source of LH in the ovarian stimulation protocol. These data
revealed a key role of PPARs in the ovarian follicle growth
and competence and widen the knowledge on the effects
of ovarian stimulation protocol on ovarian physiology. In
addition, it is well known that the action of cyclooxygenase 2-
(COX2-) derived prostacyclins which are factors essential for
embryo development, hatching, and implantation [30, 31] is
mediated byPPAR𝛽/𝛿. Indeed, blastocyst hatching is reduced
in PPARb null mice and a beneficial effect of prostacyclin
is observed in WT embryos and embryos exposed to a
synthetic PPAR𝛽/𝛿 ligand [78]. Therefore, PPAR𝛽/𝛿 may
be considered as novel therapeutic target to improve IVF
outcome.
An important effect of PPARs on steroidogenesis is
related to the ability of PPAR𝛾 to counteract the interaction
of NF-𝜅B with the aromatase promoter II [20] by inhibiting
the expression of P-450 (CYP19A1), also known as aromatase
or estrogen synthase, the rate limiting enzyme for the
conversion of androgens to estradiol. In a recent study by
Rak-Mardyła and Karpeta [21], it was observed in porcine
ovarian follicles that rosiglitazone significantly increases
PPAR𝛾 expression, progesterone secretion, 3𝛽HSDII activ-
ity, and protein expression but decreases androstenedione
and testosterone secretion by reducing the expression and
activity of 17-hydroxylase, 17,20-lyase (CYP17), and 17𝛽-
hydroxysteroid dehydrogenase (17𝛽HSD) and had no effects
on estradiol secretion and CYP19A1 activity. PPAR𝛾 can
also affect steroidogenesis by decreasing the production
of androgenic precursors in the theca cells, antagonizing
the stimulation of androstenedione, typically induced by
LH/insulin combination in disorders such as PCOS, hyper-
insulinism, oligoovulation, and hirsutism [79]. Veldhuis and
colleagues demonstrated that synthetic thiazolidinedione
(troglitazone) and a natural ligand of PPAR𝛾 impede the
concerted stimulation by LH and insulin of in vitro thecal
cell androgen production, CYP17 gene expression, andCYP17
protein phosphorylation. In porcine ovaries resistin, the
adipose tissue-specific secretory factor (ADSF) associated
with ovarian dysfunction in obese women is known to
upregulate PPAR𝛾, which, in turn, reduces resistin expres-
sion. GW9662, a synthetic PPAR𝛾 antagonist, was capable of
reversing the effect of resistin on steroid hormone secretion
[80]. In mice, the ovarian tissue-specific deletion of PPAR𝛾
led to subfertility, principally due to a decreased number of
implanted embryos and a decreased progesterone secretion
by the corpus luteum [81].
3.3. Uterus and Placenta. The expression of all PPAR isotypes
has been reported in uterus and placenta and a correla-
tion between PPARs expression profiles in uterus and the
development of placenta has been demonstrated [82]. A
species-specific expression profile of PPAR isotypes has been
observed. In sheep endometrium, PPAR𝛼 ismainly expressed
during early stages of pregnancy with a decrease between
day 7 and day 17. PPAR𝛽/𝛿 is constantly expressed during
pregnancy, whereas PPAR𝛾 expression is irregular [13]. In
addition in this animalmodel, the expression of PPARs seems
to be unrelated to the expression of RXRs, probably due to
different heterodimer composition [83]. In rodents, PPAR𝛼
and PPAR𝛽/𝛿 are expressed in the placenta labyrinth and
junctional zone, whereas in humans, they are observed in
villous trophoblasts and in particular in syncytiotrophoblasts
[84]. In the rat, the expression of PPAR𝛽/𝛿 is decreased in
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endometrial stromal cells during implantation [85]. PPAR𝛾
was also detected in mouse [86] and rat placenta [87] by
days 8 and 11, respectively. In human placenta, PPAR𝛾 is
expressed in early and full-term villous trophoblasts and
in extravillous trophoblasts in first-trimester placentas [88].
In mice PPAR𝛾 is expressed in spongiotrophoblasts, in the
vascular labyrinth necessary for maternal and fetal nutri-
ent exchange. In cultured villous trophoblasts of human
term placenta, PPAR𝛼 and PPAR𝛽/𝛿 transcript levels were
higher in cytotrophoblasts than in syncytiotrophoblasts [89].
PPAR𝛾1 is the only PPAR𝛾 isoform clearly detectable in dog
uterine/placental tissues. Placental expression of PPAR𝛾 is
elevated after implantation and atmidgestation, followed by a
prepartal downregulation. All changes are more pronounced
at the protein level suggesting that the PPAR𝛾 expressionmay
be regulated at posttranscriptional level [90].
PPARa-knockout mice are associated with increased
rates of maternal abortion, although surviving pups develop
normally, while PPARg- and PPARb-knockout mice are
embryonic-lethal due to gross placental abnormalities and
defects in placental morphogenesis, respectively [91].
PPAR𝛽/𝛿 null mutant mice showed defects in placenta
development, probably due to the involvement of PPAR𝛽/𝛿
in differentiation of trophoblast giant cells [92]; in addition
PPAR𝛽/𝛿 is also known to regulate the production of COX2-
derived prostacyclin I2, which enhances mouse blastocyst
invasion [78]. Moreover PGI2-induced PPAR𝛽/𝛿 activation
accelerates blastocyst hatching in mice [31].
PPAR𝛾 in vivo and in vitro studies indicate that inactiva-
tion of PPAR𝛾 leads to defective trophoblast differentiation,
early embryonic lethality, and severe developmental placental
damage, which together can affect the placental labyrinth
zone development [93–95]. For instance, PPAR𝛾 activity
affects trophoblast differentiation by regulating the functions
of both villocytotrophoblast (VCT) and extravillocytotro-
phoblast (EVCT) [91].
In conclusion we can assert that PPARs play important
roles as key-factors responsible for controlling the process of
placental development (for more details see review by Meher
et al., 2015 [96]).
3.4. Mammary Glands. All three isotypes of PPAR are
detected in rodent mammary gland and human breast cell
lines [97, 98]. During pregnancy and lactation, PPAR𝛼
and PPAR𝛾 mRNAs decreased while PPAR𝛽/𝛿 mRNA
remained relatively unchanged in mouse mammary gland
[97]. Changes in PPAR𝛾 and endocrine-related genes in
perfluorooctanoic acid (PFOA) treated mice delay mam-
mary gland development at weaning [99]. PPAR𝛾 adipose
tissue-specific knockout mice exhibit absence of dermal fat
and absence of mammary gland development with loss of
mammary fat pads, suggesting a critical role for PPAR𝛾
mammary gland development [100]. Moreover, its role in
regulating the triacylglycerol synthesis and secretion in goat
mammary cells outlines the functional importance of PPAR𝛾
in mammary gland tissue during lactation [101]. PPAR𝛾
loss in mammary secretory epithelial (MSE) cells results in
decreased expression of PTEN and other factors contributing
to a protumorigenic environment [102].
4. PPAR Implications in Subfertility
Female fertility and energy metabolism are tightly inter-
connected. During the reproductive life, the physiological
activity of the gonads, with their cyclic production of sex
hormones, ensures a continuous regulation of food intake
and energy expenditure. In female mammals, alterations
of gonadal activity, including age-dependent decrease of
ovarian functions, are associatedwith disruption ofmetabolic
homeostasis and consequent inflammatory reactions that
trigger the onset of metabolic, cardiovascular, skeletal, and
neural pathologies [103]. PCOS is a major metabolic and
reproductive disorder characterized by hyperandrogenism,
chronic anovulation, and polycystic ovaries [104], as well as
metabolic disturbances. Half of PCOS patients have over-
weight or obesity [105] and dyslipidemia is also commonly
observed [106]. Given the role of PPARs in regulating
energy homeostasis and carbohydrate metabolism, there is
an increasing interest in the use of its agonists for the
restoration of metabolic homeostasis in women with ovarian
dysfunction [107, 108]. Synthetic PPAR agonists are used
for therapeutic treatment of metabolic diseases, including
dyslipidemia [109], insulin resistance [110], and type 2 dia-
betes [111]. Particularly, fibrates, well-known PPAR𝛼 agonists,
are commonly prescribed for the treatment of dyslipidemia
[112]. Several TZDs, structural analogues of fibrates including
pioglitazone and rosiglitazone, improve glycemic control in
patients with type 2 diabetes or glucose intolerance via their
insulin-sensitizing activity, mainly achieved by decreasing
circulating fatty acids levels and increasing glucose uptake
in insulin-sensitive tissues, like skeletal muscle. Current data
show that TZDs can effectively reduce insulin and fasting
blood glucose levels in patients with PCOS, but they do
not effectively reduce androgen levels and seem to increase
body weight [113]. A further study has reported that low-
dose therapeutic regimen with rosiglitazone and metformin,
a hypoglycemic drug used in the treatment of diabetes, has
comparable beneficial impacts on metabolic, hormonal, and
morphological features of PCOS [114]. Positive effects of
pioglitazone, a PPAR𝛾 activator, on carnitinemetabolism and
insulin sensitivity in PCOSpatients have beendescribed [115].
Theca cells are the sole ovarian site of synthesis of DHEA,
which is a precursor of androstenedione, an essential ligand
for PPAR𝛼, and DHEA supplementation improves follicular
microenvironment in poor responder patients [76]. Recent
data have reported that administration of Irbesartan (IRB), a
PPAR𝛾 agonist, during chemotherapy alleviates the ovarian
toxicity by cyclophosphamide (CPM), a chemotherapeutic
agent. IRB coadministration restored ovarian antioxidant
defences, such as increased glutathione (GSH) levels and
superoxide dismutase (SOD) activity and decreased levels of
malondialdehyde (MDA), an indicator of lipid peroxidation.
In addition, the increase in E2 and reduction in FSH levels
observed in IRB rats support the hypothesis that ovarian
function is protected by activation of PPAR𝛾 signalling
contributing to CPMdetoxification and antioxidant response
[116] that can be explored for future implications in oncofer-
tility. In spite of the role of PPARs in ovarian homeostasis,
it is important to highlight that toxic compounds such as
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industrial plasticizers, herbicides, and organic solvents can
act as powerful PPAR agonists [8]. Unintended exposure
to chemicals having PPAR𝛼 and PPAR𝛾 agonistic activities
induces notable toxicological results, such as endocrine
disruption [117]; particularly mono(2-ethylhexyl) phthalate
MEHP is distinct from several structurally related phthalates
but similar to the peroxisome proliferator Wy-14,643 in its
action on granulosa cell estradiol production.
Among various environmental chemicals, MEHP, a met-
abolite of dioctyl terephthalate bis(2-ethylhexyl) benzene-1,4-
dicarboxylate (DEHP), transactivates PPAR𝛼 and PPAR𝛾 in
both human andmouse [118]; the triphenyltin, used as fungi-
cide, acts as a ligand of PPAR𝛾 [119]; diclofop-methyl and
pyrethrins, two common pesticides, induce PPAR𝛼 agonistic
activity in vivo as well as in vitro [120].
In a recent study the effect of the exposure to DEHP
on ovarian expression of estrogen receptor 𝛼 (Esr1) and
aromatase (Cyp19a1) in three generations of Sv/129 wild-type
(WT, +/+) and PPAR𝛼 (−/−) knockout mice is investigated.
Ovarian expression of Esr1 decreases in response to DEHP
treatment in all WT generations, but in PPAR𝛼 null mice this
treatment was ineffective, suggesting that transgenerational
repression of ovarian Esr1 gene expression by DEHP is
mediated by PPAR𝛼-dependent pathways [121].
5. Future Perspective
In conclusion, a large number of studies have demonstrated
that PPARs might play an important role in female repro-
duction, including ovarian function, gestation, and commu-
nication between mother and fetus. The use of synthetic
PPAR ligands employed to ameliorate complications related
to metabolic disorders has recently been expanded to dis-
orders in the reproductive area. Moreover, the correlation
between PPARs and steroidogenesis during follicular differ-
entiation supports further research aimed at understanding
if controlled ovarian hyperstimulation in IVF cycles may
benefit from their pharmacological manipulation. Neverthe-
less, research in this field needs to be associated with the
knowledge of mechanisms underlying deleterious effects on
fertility of uncontrolled exposure to PPAR synthetic ligands.
In conclusion, PPARs are new players in the field of
reproduction being expressed and functional in a variety
of animal reproductive tissues. In addition, from studies
with PCOS women [115, 116], it is now clarified that ligands
of PPARs ameliorate fertility. However, the knowledge on
expression and function of PPARs and its ligands in other
diseases linked to infertility and disturbed pregnancy is
limited and deserves further investigations, especially in
humans.
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